Intrexon (XON) on Watch as FDA Green Lights GM Mosquitoes
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
Intrexon (NYSE: XON) on watch as FDA green lights GM mosquitoes.
From the FDA:
The FDA has completed the environmental review for a proposed field trial to determine whether the release of Oxitec Ltd.’s genetically engineered (GE) mosquitoes (OX513A) will suppress the local Aedes aegypti mosquito population in the release area at Key Haven, Florida. After considering thousands of public comments, the FDA has published a final environmental assessment (EA) and finding of no significant impact (FONSI) that agrees with the EA’s conclusion that the proposed field trial will not have significant impacts on the environment.
FDA’s finalization of the EA and FONSI does not mean that Oxitec’s GE mosquitos are approved for commercial use. Oxitec is responsible for ensuring all other local, state, and federal requirements are met before conducting the proposed field trial, and, together with its local partner, the Florida Keys Mosquito Control District, to determine whether and when to begin the proposed field trial in Key Haven, Florida.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Pluristem Therapeutics (PSTI) Enters $30M Equity Investment Agreement with China's Innovative Medical
- DragonWave's (DRWI) Harmony Radio, Hub 800 Products Selected by Leading Australian Telecom
- Bristol-Myers Squibb (BMY) Announces New Data from Opdivo Phase 2 in cHL; ORR was 73% Across Subgroups
Create E-mail Alert Related CategoriesCorporate News, FDA, Hot Corp. News, Momentum Movers, Trader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!